Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Postma

Showing results (101-110 of 135) with videos related to

Pageof 14
Sort By:
Vaccine|June 23, 2009
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the NetherlandsR M Rogoza, T A Westra, N Ferko, et al.
BMC Cancer|March 9, 2018
Burden of early, advanced and metastatic breast cancer in The NetherlandsG T Vondeling, G L Menezes, E P Dvortsin, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 11, 2018
Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patientsM A Zuur, A D I van Asselt, N van 't Boveneind-Vrubleuskaya, et al.
Vaccine|May 8, 2012
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The NetherlandsM J Meijboom, M H Rozenbaum, A Benedictus, et al.
Journal of Chemotherapy (Florence, Italy)|May 23, 2002
The application of cost effectiveness analysis to derive a formulary for urinary tract infectionsA Tramarin, L Bragagnolo, K Tolley, et al.
Vaccine|August 21, 2007
The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approachJ M Bos, E Rietveld, H A Moll, et al.
Pharmacoeconomics - Open|August 22, 2023
Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and QualityL A de Jong, X Li, S Emamipour, et al.
Vaccine|November 9, 2004
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-makingR Welte, G van den Dobbelsteen, J M Bos, et al.
Value in Health Regional Issues|April 29, 2018
Models to Predict the Burden of Cardiovascular Disease Risk in a Rural Mountainous Region of VietnamThi Phuong Lan Nguyen, C C M Schuiling-Veninga, Thi Bach Yen Nguyen, et al.
Expert Review of Vaccines|August 20, 2016
Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza controlB M Van Maanen, P T de Boer, F C K Dolk, et al.
Pageof 14

Showing results (101-110 of 135) with videos related to

Sort By:
Pageof 14
Vaccine|June 23, 2009
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the NetherlandsR M Rogoza, T A Westra, N Ferko, et al.
BMC Cancer|March 9, 2018
Burden of early, advanced and metastatic breast cancer in The NetherlandsG T Vondeling, G L Menezes, E P Dvortsin, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 11, 2018
Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patientsM A Zuur, A D I van Asselt, N van 't Boveneind-Vrubleuskaya, et al.
Vaccine|May 8, 2012
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The NetherlandsM J Meijboom, M H Rozenbaum, A Benedictus, et al.
Journal of Chemotherapy (Florence, Italy)|May 23, 2002
The application of cost effectiveness analysis to derive a formulary for urinary tract infectionsA Tramarin, L Bragagnolo, K Tolley, et al.
Vaccine|August 21, 2007
The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approachJ M Bos, E Rietveld, H A Moll, et al.
Pharmacoeconomics - Open|August 22, 2023
Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and QualityL A de Jong, X Li, S Emamipour, et al.
Vaccine|November 9, 2004
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-makingR Welte, G van den Dobbelsteen, J M Bos, et al.
Value in Health Regional Issues|April 29, 2018
Models to Predict the Burden of Cardiovascular Disease Risk in a Rural Mountainous Region of VietnamThi Phuong Lan Nguyen, C C M Schuiling-Veninga, Thi Bach Yen Nguyen, et al.
Expert Review of Vaccines|August 20, 2016
Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza controlB M Van Maanen, P T de Boer, F C K Dolk, et al.
Pageof 14